The goal of this project is to characterise the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and leucoplasic) counterparts by scRNAseq in OSCC patients.
I1. Male or female at least 18 years old.
I2. Patient with OSCC and undergoing surgery at the Centre Léon Bérard.
I3. Patient who has agreed to participate in this research and sign consent.
I4. Patient affiliated to a medical insurance.
NI1. Pregnant or nursing woman.
NI2. Contraindication to general anesthesia.
NI3. Suspicion of rare tumor of particular histology other than squamous cell carcinoma (Sarcoma...).
NI4. Patient under curatorial or guardianship or placed under the protection of justice.
Single group
Biospecimen
Procedure/Surgery* 1 or 2 tumoral specimen (depending on the size of the tumor) * 1 specimen of the healthy oral mucosa * 1 leucoplakia specimen if applicable. The biospecimens will be collected at the time of the surgery organised for the standard routine medical care.
Blood sampling
Procedure/SurgeryBlood sampling (6 mL), taken from a routine biological exam.
Characterization of the heterogeneity of all cell populations (tumour cells, stromal and immune microenvironment) present in the tumor and their normal (and leucoplasic) counterparts by scRNAseq in OSCC patients.
Transcriptomic data from scRNAseq for all cell populations
Description of the functional interactions among tumor, stromal, and immune subpopulations identified by scRNAseq
Describe the functional interactions between tumor, stromal, and immune subpopulations using ex vivo culture models and co-culture assays. Cellular responses will be assessed using transcriptomic analysis and phenotypic characterization.
Correlation between refined patient stratification (based on tumor, stromal and immune sub-population) and the impact on the response to ex-vivo treatments.
Correlation between tumor, stromal and immune sub-populations likely to refine patient stratification and the impact on the response to ex-vivo treatments.
Identification of prognostic and predictive biomarkers for oral squamous cell carcinoma evolution
Correlation of gene expression profiles with disease progression to identify prognostic and predictive biomarkers in scRNAseq and bulk RNAseq datasets
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
